To include your compound in the COVID-19 Resource Center, submit it here.

Wilson reports Phase II extension data for Wilson’s disease candidate

Wilson Therapeutics AB (SSE:WTX) reported data from 22 patients with Wilson’s disease in the extension portion of the 24-week Phase II WTX101-201 trial showing that once-daily oral Decuprate bis-choline tetrathiomolybdate (WTX101) controlled mean nonceruloplasmin-bound copper (NCC) levels through week 48 (0.9 µm

Read the full 428 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE